beta thalassaemia

This page shows the latest beta thalassaemia news and features for those working in and with pharma, biotech and healthcare.

bluebird bio to separate oncology and rare diseases units

bluebird bio will continue to focus on delivering gene therapies in its core areas – beta-thalassaemia, cerebral adrenoleukodystrophy and sickle cell disease. ... This includes its beta-thalassaemia gene therapy betibeglogene autotemcel, which is

Latest news

ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

bluebird bio’s beta thalassaemia gene therapy Zynteglo scores promising long-term data. ... bluebird bio also posted long-term data for its own beta thalassaemia gene therapy Zynteglo (betibeglogene autotemcel) at ASH 2020.
bluebird bio’s beta thalassaemia gene therapy Zynteglo scores promising long-term data

in patients with transfusion-dependent beta thalassaemia (TDT).
EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease

LentiGlobin is approved under the brand name Zynteglo in Europe for the treatment of dependent beta thalassaemia (TDT) who do not have a matching donor for a stem cell transplant.
AstraZeneca forms $2bn gene silencing pact with Silence Tx

It is also working on its own in-house projects, namely SLN124 for beta thalassaemia, which is in phase 1b testing, and SLN360 which targets Lp(a) and is in early
Incyte launches award programme recognising innovation in GVHD community

Other developers are aiming to produce therapies which avoid the causes of GVHD – that includes bluebird bio, whose beta thalassaemia treatment Zynteglo/LentiGlobin is designed to avoid the complications of GVHD

More from news
Approximately 5 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Case-study for thalassaemia: Dimitri Azzopardi

An in-depth look at beta thalassaemia for Rare Disease Day. Beta thalassaemia major is a serious, lifelong genetic blood disorder. ... At least 75, 000 children are born. with thalassaemia worldwide every year, of which 10, 000 have the debilitating form
20 for 2020 – Five pharma companies to watch

treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Account Director: Competitive

Medical Editor: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Senior Account Manager: Competitive

Healthcare Lead Copywriter: Competitive

Account Director – Creative Healthcare Communications: Competative

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

PMHub

Add my company

Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

The pandemic preparedness paradox: Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...